Botulinum toxin a injections to the upper limbs in children with cerebral palsy: Duration of effect

Journal of Child Neurology

Volumn 26, Issue 2, 2011, Pages 166-170

  Fattal Valevski, Aviva ^a   Sagi, Liora ^a   Domenievitz, Dafna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

botulinum toxin type A; duration of effect; upper limbs

Indexed keywords

BOTULINUM TOXIN A;

ARM; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; FEMALE; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HEMIPARESIS; HUMAN; MALE; MUSCLE TONE; PRIORITY JOURNAL; QUADRIPLEGIA; SCHOOL CHILD; TIME;

ADOLESCENT; BOTULINUM TOXINS, TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UPPER EXTREMITY; YOUNG ADULT;

EID: 79551642537     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810376446     Document Type: Article

References (23)

1. Wasiak J., Hoare B., Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev. 2004 ; CD003469.
2. Wall SA, Chait LA, Temlett JA, et al. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg. 1993 ; 46: 703-706.
3. Mall V., Heinen F., Linder M., et al. Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil. 1997 ; 1: 235-237.
4. Boyd RN, Morris ME, Graham HK Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol. 2001 ;(Suppl5). 150-166.
5. Hoare B., Imms C. Upper-limb injections of botulinum toxin-A in children with cerebral palsy: a critical review of the literature and clinical implications for occupational therapists. Am J Occup Ther. 2004 ; 58: 389-397.
6. Sakzewski L., Ziviani J., Boyd R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics. 2009 ; 123: e1111 - e1122.
7. Corry IS, Cosgrove AP, Walsh EG, et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol. 1997 ; 39: 185-193.
8. Fehlings D., Rang M., Glazier J., Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000 ; 137: 331-337.
9. Speth LA, Leffers P., Janssen-Potten YJ, Vles JS Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol. 2005 ; 47: 468-473.
10. Reeuwijk A., Van Schie PE, Becher JG, Kwakkel G. Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review. Clin Rehabil. 2006 ; 20: 375-387.
11. Wallen M., O'Flaherty SJ, Waugh MC Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil. 2007 ; 88: 1-10.
12. Brin MF Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997 ; 6: S146 - S168.
13. Heinen F., Desloovere K., Schroeder S., et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Pediatr Neurol. 2010 ; 14: 45-66.
14. Palisano JR, Cameron D., Rosenbaum PL, et al. Stability of the Gross Motor Function Classification System. Dev Med Child Neurol. 2006 ; 48: 424-428.
15. Eliasson AC, Krumlinde-Sundholm L., Rösblad B., et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006 ; 48: 549-554.
16. Boyd RN, Graham HK Botulinum toxin A in the management of children with cerebral palsy-indications and outcome. Eur J Neurol. 1997 ;(Suppl): 15-22.
17. Boyd RN, Graham HK Objective clinical measures in the use of Botulinum toxin A in the management of cerebral palsy. Eur J Neurol. 1999 ;(Suppl4). 23-36.
18. Allergan Inc. BOTOX(R) (OnabotulinumtoxinA) receives FDA approval for treatment of upper limb spasticity in adults. Published: March 9th, 2010 ; agn.client.shareholder.com.
19. Sätilä H., Kotamäki A., Koivikko M., Autti-Rämö I. Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases. Pediatr Rehabil. 2006 ; 9: 247-258.
20. Autti-Rämö I., Larsen A., Taimo A., et al. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol. 2001 ; 8: 136-144.
21. Wissel J., Heinen F., Schenkel A., et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics. 1999 ; 30: 120-124.
22. Herrman J., Geth K., Mall V., et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 2004 ; 55: 732-735.
23. Fattal-Valevski A., Domenievitz D., Giladi N., et al. Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy-A prospective study. J Child Orthop. 2008 ; 2: 29-35.